	US 12,312,592 B2
	Retroviral vector
Hannah Stewart, Oxford (GB); Helen Maunder, Bicester (GB); Kyriacos Mitrophanous, Oxford (GB); and Daniel Farley, Oxford (GB)
Assigned to Oxford BioMedica (UK) Limited, Oxford (GB)
Filed by Oxford BioMedica (UK) Limited, Oxford (GB)
Filed on Feb. 7, 2023, as Appl. No. 18/106,972.
Application 18/106,972 is a continuation of application No. 16/231,349, filed on Dec. 21, 2018, abandoned.
Claims priority of application No. 17210359 (EP), filed on Dec. 22, 2017.
Prior Publication US 2023/0183745 A1, Jun. 15, 2023
Int. Cl. C12N 15/86 (2006.01)

CPC C12N 15/86 (2013.01) [C12N 2740/10041 (2013.01); C12N 2740/10052 (2013.01); C12N 2740/13051 (2013.01); C12N 2740/13052 (2013.01); C12N 2740/15051 (2013.01); C12N 2740/15052 (2013.01); C12N 2740/16051 (2013.01); C12N 2740/16052 (2013.01)]

12 Claims

1. A bacterial plasmid comprising nucleic acid sequences encoding env and rev in reverse orientations, wherein the nucleic acid sequences encoding env and rev are each operably linked to at least one transcription regulation element selected from the tetracycline repressor (TetR) group of transcription regulators or from the cumate inducible switch system transcription regulators.